News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 718
- Sources here
- 16
- Companies here
- 19
Active search
718 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Medallion Financial (NASDAQ:MFIN) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
Medallion Financial (MFIN) shares have surpassed their 200-day moving average, trading at $11.43 against an average of $9.72. Despite this, analysts maintain a "Hold" rating with a $10.50 target price, which is below the current trading level. The company recently exceeded earnings and revenue …
Consumer Portfolio Services (CPSS) awards 60,000 options to senior vice president
Consumer Portfolio Services (CPSS) announced that its Sr. Vice President, Michele L. Baumeister, was granted 60,000 stock options on August 11, 2026. These options have an exercise price of $9.20 per share and will vest in four equal installments annually from August 2027 to …
Maurice Duca (APPF) details 6.41M-share AppFolio stake and 44.7% voting power
Maurice J. Duca has filed an amended Schedule 13D, reporting a beneficial ownership of 6,410,682 Class A Shares in AppFolio, Inc., which represents 21.2% of the outstanding Class A shares as of August 13, 2026. His total holdings, including Class B shares, account for …
Lionheart Holdings (NYSE: CUB) sees 6.52% stake reported by Decagon Asset Management
Decagon Asset Management LLP and Benjamin John Durham have reported a beneficial ownership of 1,500,000 Class A ordinary shares in Lionheart Holdings (NYSE: CUB), which constitutes a 6.52% stake in the company. Both parties maintain sole voting and dispositive power over these shares, with …
AppFolio General Counsel Evan Pickering Sells 727 Shares
Key Points The disposition involved 727 shares with a total transaction value of ~$146,000. The activity reduced the executive's direct equity position by 12%. Disclosed activity consisted of 264 shares withheld for tax obligations and 463 shares sold under a Rule 10b5-1 trading plan. …
AQR group discloses 1.4M Lionheart Holdings shares in 13G/A filing (CUB)
AQR Capital Management, LLC, along with AQR Capital Management Holdings, LLC and AQR Arbitrage, LLC, has disclosed an amended beneficial ownership of 1,400,000 Class A ordinary shares in Lionheart Holdings (CUB), representing 6.51% of the outstanding class. The entities hold shared voting and dispositive …
Twilio Director Andrew Stafman Sells 500,000 Shares for $123.5 Million
Andrew Stafman, Director at Twilio Inc. (NYSE:TWLO), sold ~500,000 shares of Class A Common Stock on August 12, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $123.5 million Shares sold (indirectly held) ~500,000 Post-transaction shares ~133,000 Post-transaction shares (directly held) 13,492 …
Sharemaestro market context Trend signal active 52 weeks +131.1%Valion Bio (Nasdaq:VBIO) - analisi del titolo
This article provides an analysis of Valion Bio (Nasdaq: VBIO), an advanced-stage biopharmaceutical company with a market capitalization of US$546.7k. The company is developing Entolimod for Acute Radiation Syndrome (ARS) and oncology supportive care, facing significant risks including a highly volatile stock price, declining …
Entolimod Could Receive Its First National Registration in Ukraine
Valion Bio (Nasdaq: VBIO) announced that Ukraine's Ministry of Health has accepted the regulatory dossier for its ARS countermeasure, Entolimod, for formal review. A favorable decision, which could come as early as Q4 2026, would mark Entolimod's first national registration and could lead to …
Here's How Much You'd Have If You Invested $1000 in Twilio a Decade Ago
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in …
Sharemaestro market context Trend signal active 52 weeks +131.1%AppFolio director Maurice Duca sells $1.09m in shares By Investing.com
Maurice J. Duca, a director and 10% owner of AppFolio Inc. (NASDAQ:APPF), sold 5,442 shares of Class A Common Stock for over $1 million on August 11, 2026, as part of a pre-arranged trading plan. Despite the sale, InvestingPro analysis suggests AppFolio's stock is …
Valion Bio, Inc. SEC Filing (Aug 13, 2026)
This article reports on Valion Bio, Inc.'s SEC Filing of type EFFECT on August 13, 2026. The filing has a neutral impact and sentiment, indicating that it is a routine notice of effectiveness for an S-1 registration form. The filing concerns Valion Bio, Inc. …
Lionsgate Studios Corp. (NYSE:LION) Receives Average Recommendation of "Moderate Buy" from Analysts
Lionsgate Studios Corp. (NYSE:LION) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $15.575, exceeding its current share price of $11.73. Recent analyst actions include downgrades to "neutral" by Citigroup and Zacks Research, while Barrington Research and …
Is Upgraded Guidance and Data Center Focus Altering The Investment Case For Helios Technologies (HLIO)?
Helios Technologies (HLIO) reported strong Q2 2026 results, raising full-year guidance and completing its business stabilization plan. The company is now entering a "takeoff" phase, targeting data center thermal management as a key growth area. While continued buybacks and dividends add appeal, the stock …
AppFolio principal accounting officer Don Rigler sells $29,380 in shares By Investing.com
Don Rigler, Principal Accounting Officer at AppFolio Inc. (NASDAQ:APPF), sold 150 shares of Class A Common Stock for $29,380 and disposed of 107 additional shares to cover tax withholding obligations. These transactions occurred on August 10, 2026, as per a pre-arranged plan. Rigler now …
BillionToOne (BLLN) SVP sells 1,417 shares in Rule 10b5-1 planned trade
BillionToOne, Inc.'s Senior Vice President of Laboratory Operations, John Roderick ten Bosch, sold 1,417 shares of Class A Common Stock on August 10, 2026, at $92.86 per share, totaling approximately $132,000. This transaction was conducted under a Rule 10b5-1 trading plan established on March …
Twilio director Andrew Stafman sells $123.5 million in shares
Twilio director Andrew Stafman sold 500,000 shares of Class A Common Stock for $123.5 million on August 12, 2026, at $247.08 per share. This sale occurred as Twilio's stock traded near its 52-week high after a 142% gain. The transaction details also highlight Stafman's …
Twilio (TWLO) stake trimmed as Sachem Head-linked funds sell 500K shares
Funds linked to Sachem Head Capital Management LP, including Twilio director Andrew J. Stafman, sold 500,000 shares of Twilio Inc. Class A common stock at $247.08 per share. Following the transaction, the entities indirectly hold 120,000 shares, while Stafman directly holds 13,492 shares. The …
Twilio Inc. (TWLO) director’s trust sells 3,500 shares under 10b5-1 plan
Erika Rottenberg, a director at Twilio Inc. (TWLO), through her revocable trust, sold 3,500 Class A Common Stock shares on August 10, 2026. The sales were executed in six open-market transactions under a Rule 10b5-1 trading plan established on December 10, 2025, with prices …
Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS
Xilio Therapeutics (NASDAQ:XLO) announced its earnings results, reporting an adjusted loss of $0.33 per share, which beat analyst estimates by $0.26. The company's revenue of $18.69 million also surpassed expectations, though Xilio Therapeutics remains unprofitable with a negative net margin. Despite institutional investor ownership …
Xilio Therapeutics Releases Q2 2026 Financial Results
Xilio Therapeutics (XLO) reported its Q2 2026 financial results, showing a narrower net loss of $0.33 per share, an 85.3% improvement year-over-year. Revenue significantly increased by 131.2% to $18.7 million compared to Q2 2025. The company specializes in tumor-activated immuno-oncology therapies and continues to …